Objective: To estimate the effect of tocilizumab or glucocorticoids in preventing death and intubation in patients hospitalized with SARS-CoV-2 pneumonia.Methods: This was a retrospective cohort study enrolling all consecutive patients hospitalized at Reggio Emilia AUSL between February the 11th and April 14th 2020 for severe COVID19 and treated with tocilizumab or glucocorticoids (at least 80 mg/day of methylprednisolone or equivalent for at least 3 days).The primary outcome was death within 30 days from the start of the considered therapies. The secondary outcome was a composite outcome of death and/or intubation. All patients have been followed-up until May 19th 2020, with a follow-up of at least 30 days for every patient. To reduce confounding due to potential non-comparability of the two groups, those receiving tocilizumab and those receiving glucocorticoids, a propensity score was calculated as the inverse probability weighting of receiving treatment conditional on the baseline covariates.Results and conclusion: Therapy with tocilizumab alone was associated with a reduction of deaths (OR 0.49, 95% CI 0.21-1.17) and of the composite outcome death/intubation (OR 0.35, 95% CI 0.13-0.90) compared to glucocorticoids alone. Nevertheless, this result should be cautiously interpreted due to a potential prescription bias.(c) 2021 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study / Dolci, G; Cassone, G; Besutti, G; Corsini, R; Sampaolesi, F; Iotti, V; Galli, E; Palermo, A; Fontana, M; Mancuso, P. - In: THE BRAZILIAN JOURNAL OF INFECTIOUS DISEASES. - ISSN 1413-8670. - 26:1(2022), pp. N/A-N/A. [10.1016/j.bjid.2021.1017021413-8670]

Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study

Dolci, G;Cassone, G;Besutti, G;Corsini, R;Galli, E;Palermo, A;
2022

Abstract

Objective: To estimate the effect of tocilizumab or glucocorticoids in preventing death and intubation in patients hospitalized with SARS-CoV-2 pneumonia.Methods: This was a retrospective cohort study enrolling all consecutive patients hospitalized at Reggio Emilia AUSL between February the 11th and April 14th 2020 for severe COVID19 and treated with tocilizumab or glucocorticoids (at least 80 mg/day of methylprednisolone or equivalent for at least 3 days).The primary outcome was death within 30 days from the start of the considered therapies. The secondary outcome was a composite outcome of death and/or intubation. All patients have been followed-up until May 19th 2020, with a follow-up of at least 30 days for every patient. To reduce confounding due to potential non-comparability of the two groups, those receiving tocilizumab and those receiving glucocorticoids, a propensity score was calculated as the inverse probability weighting of receiving treatment conditional on the baseline covariates.Results and conclusion: Therapy with tocilizumab alone was associated with a reduction of deaths (OR 0.49, 95% CI 0.21-1.17) and of the composite outcome death/intubation (OR 0.35, 95% CI 0.13-0.90) compared to glucocorticoids alone. Nevertheless, this result should be cautiously interpreted due to a potential prescription bias.(c) 2021 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
26
1
N/A
N/A
Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study / Dolci, G; Cassone, G; Besutti, G; Corsini, R; Sampaolesi, F; Iotti, V; Galli, E; Palermo, A; Fontana, M; Mancuso, P. - In: THE BRAZILIAN JOURNAL OF INFECTIOUS DISEASES. - ISSN 1413-8670. - 26:1(2022), pp. N/A-N/A. [10.1016/j.bjid.2021.1017021413-8670]
Dolci, G; Cassone, G; Besutti, G; Corsini, R; Sampaolesi, F; Iotti, V; Galli, E; Palermo, A; Fontana, M; Mancuso, P
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1413867021001719-main.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 314.58 kB
Formato Adobe PDF
314.58 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1274761
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact